Utah Medical Products, Inc. (UTMD)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$71.10+0.55%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · UTMD
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 9 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $71 UTMD trades at 22× p/e, below its 23× p/e peer median, but our blended $65 fair value sits below the price. It's a high-confidence read. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| dcf fcfe | 12M | $25.30 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $52.79 | — | — | Hist. CAGR | high |
| graham number | 12M | $53.17 | — | — | TTM | high |
| Peer P/FCF | 12M | $94.98 | 26.4 | 3.60 | TTM | high |
| Peer P/E | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Roughly priced in line with peers.
Around its own typical valuation.
Trailing four: 2025-Q3, 2025-Q4, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $76.66 |
| 23.4 |
| 3.28 |
| TTM |
| high |
| Peer P/S | 12M | $34.32 | 3.0 | 11.34 | TTM | high |
| residual income | 12M | $40.11 | — | — | TTM | high |
| Own P/E history | 12M | $69.67 | 21.3 | 3.28 | TTM | high |
| triangulated | 12M | $78.15 | 23.4 | 3.34 | Triangulated | high |
| Peer P/FCF | 3Y | $48.59 | 26.4 | 1.84 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $74.83 | 23.4 | 3.20 | Hist. CAGR(prov.) | medium |
| Peer P/S | 3Y | $23.87 | 3.0 | 7.89 | Hist. CAGR(prov.) | medium |
| Own P/E history | 3Y | $68.00 | 21.3 | 3.20 | Hist. CAGR(prov.) | medium |
| Peer P/FCF | 5Y | $31.08 | 26.4 | 1.18 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $58.74 | 23.4 | 2.51 | Hist. CAGR(prov.) | high |
| Peer P/S | 5Y | $18.74 | 3.0 | 6.19 | Hist. CAGR(prov.) | high |
| Own P/E history | 5Y | $53.38 | 21.3 | 2.51 | Hist. CAGR(prov.) | high |